210 related articles for article (PubMed ID: 36266034)
1. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
Yang J; Janjigian YY
Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
[TBL] [Abstract][Full Text] [Related]
2. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
3. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N; Sohal D
Cancer Immunol Immunother; 2023 Dec; 72(12):3939-3952. PubMed ID: 37995002
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Esophageal Squamous Cell Carcinoma.
Kojima T; Doi T
Curr Oncol Rep; 2017 May; 19(5):33. PubMed ID: 28361224
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for the treatment of advanced esophageal cancer.
Harada K; Yamamoto S; Kato K
Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
[TBL] [Abstract][Full Text] [Related]
8. [History and Perspective of Chemotherapy in Advanced Esophageal Cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract][Full Text] [Related]
9. Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
Kono K; Mimura K; Yamada R; Ujiie D; Hayase S; Tada T; Hanayama H; Min AKT; Shibata M; Momma T; Saze Z; Ohki S
Esophagus; 2018 Jan; 15(1):1-9. PubMed ID: 29892809
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H; Liu J; Zhang J
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
14. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
Sewastjanow-Silva M; Yamashita K; Rosa Vicentini E; Hirschmann M; Pool Pizzi M; Trail AM; Waters RE; Rogers JE; Ajani JA
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1177-1181. PubMed ID: 36266061
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
18. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
Peng C; Cohen DJ
Expert Opin Pharmacother; 2021 Jan; 22(1):93-107. PubMed ID: 33034212
[TBL] [Abstract][Full Text] [Related]
19. Immuno-oncology for esophageal cancer.
Yamamoto S; Kato K
Future Oncol; 2020 Nov; 16(32):2673-2681. PubMed ID: 32777942
[TBL] [Abstract][Full Text] [Related]
20. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
Gao HJ; Shang XB; Yu ZT
Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
